
Neulasta® Onpro® RDI Brochure
This resource details what you need to know about Neulasta®.
View and download a wealth of educational resources.
This resource details what you need to know about Neulasta®.
An easy-to-reference brochure.
See how Neulasta® can be used for different patient experiences.
A helpful resource for your patients about Neulasta®.
Use this form to help conduct patient risk assessment of FN at the first and every cycle.
A digital brochure about DKd treatment.
A one-page resource detailing DKd treatment.
Learn about the different dosing regimens for your patients.
This resource includes information on efficacy, dosing, and patient profiles.
This resource includes information on efficacy, dosing, and patient profiles.
Watch this video on Minimal Residual Disease (MRD).
A convenient resource about 5-year OS.
Learn all about the MOA of BLINCYTO® in this video.
Visit this website for information about the BLINCYTO® Risk Evaluation and Mitigation Strategy (REMS).
An easy-to-reference fact sheet about the BLINCYTO® Risk Evaluation and Mitigation Strategy (REMS).
Learn more about BLINCYTO®.
This fact sheet provides guidance on storage and handling requirements including shipping, expiration, and additional product information.
This detail aid is a helpful resource for information on efficacy, safety, dosing, and financial assistance for your patients.
This detail aid is a helpful resource for information on efficacy, safety, dosing, and financial assistance for your patients.
A convenient brochure detailing the efficacy of XGEVA®.
A helpful resource in managing patients after a diagnosis.
This resource guide details supply, preparation, administration, and coding guidance. It also includes a product fact sheet and support programs.
This resource guide details supply, storage, preparation, administration, dosing, billing, and support service guidance.
This resource guide details preparation, administration, dosing, and coding information, as well as a product fact sheet and support program information.
Use this guide for information about dosing schedule, administration prep, infusion rates, patient consultations, and storage.
A helpful resource for your patients about MVASI™.
A helpful resource for your patients about KANJINTI™.
A helpful resource for your patients about RIABNI™.
This resource helps provide guidance related to your patients' treatment while also helping your office with reimbursement and benefit verifications.
The Amgen FIRST STEP™ Program is here to help all eligible commercially insured patients who have been prescribed certain Amgen products.
Learn about the rapidly evolving landscape of biomarkers in NSCLC, including the KRAS G12C mutation which occurs in 13% of patients with NSCLC.1
Learn about KRAS and KRAS G12C mutations in cancer.
Amgen's CodeBreaK program is actively recruiting patients with the KRAS G12C mutation for studies.
Learn about the mechanism of action and the potential promise of the BiTE® Immuno-Oncology Platform.
This video provides an overview of the role of BCMA in multiple myeloma, as well as the mechanism of action of BCMA-targeted BiTE® molecules.
Listen to a conversation about biomarker testing considerations in the NSCLC landscape.
Watch this video on Minimal Residual Disease (MRD).
Learn all about the MOA of BLINCYTO® in this video.